JP2017512794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512794A5 JP2017512794A5 JP2016559249A JP2016559249A JP2017512794A5 JP 2017512794 A5 JP2017512794 A5 JP 2017512794A5 JP 2016559249 A JP2016559249 A JP 2016559249A JP 2016559249 A JP2016559249 A JP 2016559249A JP 2017512794 A5 JP2017512794 A5 JP 2017512794A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- trifluoromethyl
- benzamide
- pyrazole
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 tetrahydronaphthyridinyl Chemical group 0.000 claims 346
- 125000000623 heterocyclic group Chemical group 0.000 claims 39
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 20
- 239000001257 hydrogen Substances 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 150000002431 hydrogen Chemical group 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010067601 Dysmyelination Diseases 0.000 claims 2
- IOORZMBILFXYQY-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CC(=O)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CC(=O)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C IOORZMBILFXYQY-UHFFFAOYSA-N 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- NDGNKOKRFUFATL-UHFFFAOYSA-N 6-[5-[[2-fluoro-5-(1H-pyrazol-5-yl)-4-(trifluoromethyl)benzoyl]amino]-6-phenylpyridin-3-yl]-N-methylpyridine-3-carboxamide Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)NC)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 NDGNKOKRFUFATL-UHFFFAOYSA-N 0.000 claims 1
- GNBROKXSIMUYMP-UHFFFAOYSA-N C(C)(=O)N1CC=2C=C(C(=NC2CC1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O Chemical compound C(C)(=O)N1CC=2C=C(C(=NC2CC1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O GNBROKXSIMUYMP-UHFFFAOYSA-N 0.000 claims 1
- AEAGEILBJIDBFR-UHFFFAOYSA-N C(C)(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O Chemical compound C(C)(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O AEAGEILBJIDBFR-UHFFFAOYSA-N 0.000 claims 1
- FVJAUCAVHYAINU-UHFFFAOYSA-N C(C)(=O)NCC=1C=NC(=NC=1)C=1C=C(C(=NC=1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O Chemical compound C(C)(=O)NCC=1C=NC(=NC=1)C=1C=C(C(=NC=1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O FVJAUCAVHYAINU-UHFFFAOYSA-N 0.000 claims 1
- JHJRTSFXFZTQBX-UHFFFAOYSA-N CC(=O)N1CCC2=NC(=C(NC(=O)C3=CC(C4=NC=CC=N4)=C(C=C3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound CC(=O)N1CCC2=NC(=C(NC(=O)C3=CC(C4=NC=CC=N4)=C(C=C3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 JHJRTSFXFZTQBX-UHFFFAOYSA-N 0.000 claims 1
- PSZAYWQTGPVGTP-UHFFFAOYSA-N CN1C=CC(=N1)C1=C(C=CC(=C1)C(=O)NC1=C(N=C2CCN(CC(O)=O)CC2=C1)C1=CC=CC=C1)C(F)(F)F Chemical compound CN1C=CC(=N1)C1=C(C=CC(=C1)C(=O)NC1=C(N=C2CCN(CC(O)=O)CC2=C1)C1=CC=CC=C1)C(F)(F)F PSZAYWQTGPVGTP-UHFFFAOYSA-N 0.000 claims 1
- XXAZNUDCXFTURA-UHFFFAOYSA-N CN1C=CC(=N1)C1=CC(C(=O)NC2=C(N=C3CCN(CC3=C2)C(N)=O)C2=CC=CC=C2)=C(F)C=C1C(F)(F)F Chemical compound CN1C=CC(=N1)C1=CC(C(=O)NC2=C(N=C3CCN(CC3=C2)C(N)=O)C2=CC=CC=C2)=C(F)C=C1C(F)(F)F XXAZNUDCXFTURA-UHFFFAOYSA-N 0.000 claims 1
- ATLNHWLHOWOCPK-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N ATLNHWLHOWOCPK-UHFFFAOYSA-N 0.000 claims 1
- YRZMKDCYKMJIOW-UHFFFAOYSA-N CNC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound CNC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 YRZMKDCYKMJIOW-UHFFFAOYSA-N 0.000 claims 1
- ARQMJVYNILTACL-UHFFFAOYSA-N CS(=O)(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound CS(=O)(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 ARQMJVYNILTACL-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- RJWTUKDPJFFNLD-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C(C(=O)O)(C)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C(C(=O)O)(C)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C RJWTUKDPJFFNLD-UHFFFAOYSA-N 0.000 claims 1
- NDKZGTKXNHDWAO-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NDKZGTKXNHDWAO-UHFFFAOYSA-N 0.000 claims 1
- ZANJVJFOGFOABD-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1OC(CC1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1OC(CC1)C ZANJVJFOGFOABD-UHFFFAOYSA-N 0.000 claims 1
- LBNDRHGWPOXBLZ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=CC(=C1F)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)C)C2=CC=CC=C2)C=CC(=C1F)C LBNDRHGWPOXBLZ-UHFFFAOYSA-N 0.000 claims 1
- WSEWGTPRJVCSCN-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(CCCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(CCCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C WSEWGTPRJVCSCN-UHFFFAOYSA-N 0.000 claims 1
- KAHBJSTXGJGOJC-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(NCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CN2C(NCC2)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C KAHBJSTXGJGOJC-UHFFFAOYSA-N 0.000 claims 1
- NQENVZQSBBRBTK-QHCPKHFHSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(=O)[C@H]2NCCOC2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(=O)[C@H]2NCCOC2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C NQENVZQSBBRBTK-QHCPKHFHSA-N 0.000 claims 1
- DRBLJQCLFSZGHS-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(CO)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC(=NC2)CNC(CO)=O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C DRBLJQCLFSZGHS-UHFFFAOYSA-N 0.000 claims 1
- QSTKCWODVOZGLR-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=3CN(CCC=3C=2)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC=3CN(CCC=3C=2)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C QSTKCWODVOZGLR-UHFFFAOYSA-N 0.000 claims 1
- TUVKHJJOKKVQQH-HNNXBMFYSA-N FC1=C(C(=O)NC=2C(=NC=C(C(=O)N[C@H](CO)C)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C(=O)N[C@H](CO)C)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C TUVKHJJOKKVQQH-HNNXBMFYSA-N 0.000 claims 1
- UDKLHKLQJOGEQR-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=C(C(=O)O)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C(=O)O)C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C UDKLHKLQJOGEQR-UHFFFAOYSA-N 0.000 claims 1
- WOVTWROWYKFHAE-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=C(C2)OC2=NC=CC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C2)OC2=NC=CC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 WOVTWROWYKFHAE-UHFFFAOYSA-N 0.000 claims 1
- RTOLLHUTQWJUHJ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C(=NC=C(C2)OCC2=CC=NC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C(=NC=C(C2)OCC2=CC=NC=C2)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 RTOLLHUTQWJUHJ-UHFFFAOYSA-N 0.000 claims 1
- KQWHGGROQFESOJ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C KQWHGGROQFESOJ-UHFFFAOYSA-N 0.000 claims 1
- GSVOXRLXMKHISS-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=C2)C(=O)O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C GSVOXRLXMKHISS-UHFFFAOYSA-N 0.000 claims 1
- MZYWWXMRVIWOLM-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=C(C=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 MZYWWXMRVIWOLM-UHFFFAOYSA-N 0.000 claims 1
- OJCXAZXUSBQVST-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=CC(=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C2=NC=CC(=N2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 OJCXAZXUSBQVST-UHFFFAOYSA-N 0.000 claims 1
- SLWUKEMUEDNUNQ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C=2C=NC(=NC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)C=2C=NC(=NC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 SLWUKEMUEDNUNQ-UHFFFAOYSA-N 0.000 claims 1
- NFWDOQSKAKERAA-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)N2CCN(CC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2C=C(C=NC2C2=CC=CC=C2)N2CCN(CC2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NFWDOQSKAKERAA-UHFFFAOYSA-N 0.000 claims 1
- DTNLVCAQKQJIQZ-UHFFFAOYSA-N FC1=C(C(=O)NC=2C=C(N=NC2C2=CC=CC=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=C(N=NC2C2=CC=CC=C2)C(=O)N)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C DTNLVCAQKQJIQZ-UHFFFAOYSA-N 0.000 claims 1
- PRMAXJDIOLIDRZ-DEOSSOPVSA-N FC1=C(C(=O)NC=2C=CC(=NC2C2=CC=CC=C2)CNC(=O)[C@H]2NC(CC2)=O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2C=CC(=NC2C2=CC=CC=C2)CNC(=O)[C@H]2NC(CC2)=O)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C PRMAXJDIOLIDRZ-DEOSSOPVSA-N 0.000 claims 1
- VANNZTMUYUEAHF-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)NCC=1C=NC=CC1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)NCC=1C=NC=CC1 VANNZTMUYUEAHF-UHFFFAOYSA-N 0.000 claims 1
- ZNVLHMJZALQWMO-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1C=C(C=NC1C1=CC=CC=C1)C(=O)N ZNVLHMJZALQWMO-UHFFFAOYSA-N 0.000 claims 1
- MZVNKKLFPVLAEH-UHFFFAOYSA-N FC1=C(C=C(C2=NC=CC=C2)C(=C1)C(F)(F)F)C(=O)NC1=C(N=C2CCNCC2=C1)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C2=NC=CC=C2)C(=C1)C(F)(F)F)C(=O)NC1=C(N=C2CCNCC2=C1)C1=CC=CC=C1 MZVNKKLFPVLAEH-UHFFFAOYSA-N 0.000 claims 1
- YCRBMKFWWJXTON-UHFFFAOYSA-N NC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 Chemical compound NC(=O)N1CCC2=NC(=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)C=C2C1)C1=CC=CC=C1 YCRBMKFWWJXTON-UHFFFAOYSA-N 0.000 claims 1
- JLBSYBPJDMIGOD-UHFFFAOYSA-N NC(CC1=CC(=C(C=N1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)C1=CC=CC=C1)=O Chemical compound NC(CC1=CC(=C(C=N1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)C1=CC=CC=C1)=O JLBSYBPJDMIGOD-UHFFFAOYSA-N 0.000 claims 1
- UKKIANWEKPYPBV-UHFFFAOYSA-N NC(CC1=CC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=CC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O UKKIANWEKPYPBV-UHFFFAOYSA-N 0.000 claims 1
- IQZPJKBIANCQMG-UHFFFAOYSA-N NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=C1)C(F)(F)F)F)=O)=O IQZPJKBIANCQMG-UHFFFAOYSA-N 0.000 claims 1
- MUTFGNVCUSLFKO-UHFFFAOYSA-N NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O)=O MUTFGNVCUSLFKO-UHFFFAOYSA-N 0.000 claims 1
- OTFCRUXLUASLQC-UHFFFAOYSA-N NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O)=O Chemical compound NC(CC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NNC=C1)C(F)(F)F)F)=O)=O OTFCRUXLUASLQC-UHFFFAOYSA-N 0.000 claims 1
- WSBRAROLRNMMAF-UHFFFAOYSA-N NC1=NC(=C(C=C1C(=O)N)NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)C1=CC=CC=C1 Chemical compound NC1=NC(=C(C=C1C(=O)N)NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)C1=CC=CC=C1 WSBRAROLRNMMAF-UHFFFAOYSA-N 0.000 claims 1
- IIVDCUPTRDMNJC-UHFFFAOYSA-N OCC(=O)NCC1=CC(=C(C=N1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O)C1=CC=CC=C1 Chemical compound OCC(=O)NCC1=CC(=C(C=N1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O)C1=CC=CC=C1 IIVDCUPTRDMNJC-UHFFFAOYSA-N 0.000 claims 1
- OOYFDNGSKVIFNT-UHFFFAOYSA-N OCC(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound OCC(=O)NCC1=NC=C(C(=N1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O OOYFDNGSKVIFNT-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 claims 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/074145 WO2015143654A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| CNPCT/CN2014/074145 | 2014-03-26 | ||
| PCT/US2015/021936 WO2015148344A2 (en) | 2014-03-26 | 2015-03-23 | Trka kinase inhibitors, compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512794A JP2017512794A (ja) | 2017-05-25 |
| JP2017512794A5 true JP2017512794A5 (enExample) | 2018-05-10 |
Family
ID=54193895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016559249A Pending JP2017512794A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9815846B2 (enExample) |
| EP (1) | EP3122346B1 (enExample) |
| JP (1) | JP2017512794A (enExample) |
| KR (1) | KR20160128420A (enExample) |
| CN (1) | CN106794161A (enExample) |
| AU (1) | AU2015236428B2 (enExample) |
| BR (1) | BR112016022069A2 (enExample) |
| CA (1) | CA2943858A1 (enExample) |
| MX (1) | MX2016012480A (enExample) |
| RU (1) | RU2672583C2 (enExample) |
| WO (2) | WO2015143654A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201701928RA (en) | 2014-09-12 | 2017-04-27 | Antibiotx Aps | Antibacterial use of halogenated salicylanilides |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| GB201604484D0 (en) | 2016-03-16 | 2016-04-27 | Antibiotx Aps And Københavns Uni University Of Copenhagen | Topical antibacterial compositions |
| JP6965083B2 (ja) * | 2017-10-04 | 2021-11-10 | 公益財団法人微生物化学研究会 | 化合物、及び発光化合物 |
| CN108794414B (zh) * | 2018-06-22 | 2021-01-01 | 浙江大学 | 芳酰胺基取代的均三嗪类化合物及制备和应用 |
| CN108997224B (zh) * | 2018-08-28 | 2023-04-28 | 韶远科技（上海)有限公司 | 一种2-氯-5-氰基含氮六元杂环化合物的制备方法 |
| ES2997190T3 (en) | 2018-12-20 | 2025-02-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| CA3123042A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Kif18a inhibitors |
| CA3123227A1 (en) | 2018-12-20 | 2020-06-25 | Amgen Inc. | Heteroaryl amides useful as kif18a inhibitors |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| CN114401953A (zh) * | 2019-08-02 | 2022-04-26 | 美国安进公司 | Kif18a抑制剂 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20230193311A1 (en) | 2020-05-20 | 2023-06-22 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| TW202210467A (zh) | 2020-05-28 | 2022-03-16 | 美商美國禮來大藥廠 | TrkA抑制劑 |
| WO2022090101A1 (en) | 2020-10-26 | 2022-05-05 | Boehringer Ingelheim International Gmbh | Process for synthesis of 2,4-dichloro-5-aminopyrimidine |
| EP4402137A4 (en) * | 2021-09-14 | 2025-10-15 | Univ Vanderbilt | PHENYL RING COMPOUNDS AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU5 AND METHODS OF PRODUCTION AND USE THEREOF |
| CN113880724A (zh) * | 2021-12-06 | 2022-01-04 | 南京桦冠生物技术有限公司 | 一种3-(2-氨基苯基)-2-丙烯酸酯的制备方法 |
| WO2023211256A1 (ko) * | 2022-04-29 | 2023-11-02 | 제일약품주식회사 | 신규한 pim 키나아제 억제 화합물 및 이의 용도 |
| WO2024233922A2 (en) * | 2023-05-10 | 2024-11-14 | Texas Tech University System | Pyridine-piperazine-based scaffolds as highly potent and selective neurolysin activators |
| WO2024244972A1 (zh) * | 2023-05-30 | 2024-12-05 | 浙江海正药业股份有限公司 | 芳香酰胺类衍生物及其制备方法和用途 |
| CN116751115A (zh) * | 2023-07-03 | 2023-09-15 | 苏州诚和医药化学有限公司 | 一种间甲氧基氯苄的制备方法 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4638014A (en) | 1985-08-26 | 1987-01-20 | Research Corporation | Anticonvulsant method and formulations |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| CA2378241A1 (en) | 1999-08-04 | 2001-02-15 | Icagen, Inc. | Benzanilides as potassium channel openers |
| HN2001000008A (es) * | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| DK1575517T3 (da) | 2002-12-24 | 2012-05-14 | Rinat Neuroscience Corp | Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme |
| ES2370463T3 (es) | 2003-05-01 | 2011-12-16 | Bristol-Myers Squibb Company | Compuestos de pirazol - amida sustituidos con arilo útiles como inhibidores de quinasa. |
| MXPA06000583A (es) | 2003-07-15 | 2006-03-30 | Amgen Inc | Anticuerpos neutralizantes anti-ngf humano como inhibidores selectivos de la via del ngf. |
| EP1667983A4 (en) | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| EP2295427A1 (en) | 2004-04-30 | 2011-03-16 | Bayer HealthCare, LLC | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| DE602006015431D1 (de) | 2005-02-16 | 2010-08-26 | Astrazeneca Ab | Chemische verbindungen |
| WO2006094236A1 (en) | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | N-phenyl benzamide derivatives as sirtuin modulators |
| US20090005396A1 (en) | 2005-04-27 | 2009-01-01 | Astrazeneca Ab | Use of Pyrazolyl-Pyrimidine Derivatives in the Treatment of Pain |
| KR20080015409A (ko) | 2005-05-16 | 2008-02-19 | 아스트라제네카 아베 | 티로신 키나제 억제제로서 유용한 피라졸릴아미노피리미딘 유도체 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
| WO2007019345A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| WO2007042321A2 (en) | 2005-10-13 | 2007-04-19 | Devgen N.V. | Kinase inhibitors |
| WO2007069773A1 (en) | 2005-12-15 | 2007-06-21 | Shionogi & Co., Ltd. | A pharmaceutical composition comprising an amide derivative |
| JP5153773B2 (ja) | 2006-07-07 | 2013-02-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | フェニル置換ヘテロアリール誘導体及び抗癌剤としてのその使用 |
| AU2007315234A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| PE20090044A1 (es) | 2007-04-06 | 2009-01-23 | Neurocrine Biosciences Inc | Antagonistas del receptor de la hormona liberadora de gonadotropina y procedimientos relacionados con los mismos |
| WO2008133273A1 (ja) * | 2007-04-24 | 2008-11-06 | Shionogi & Co., Ltd. | アルツハイマー症治療用医薬組成物 |
| TW200916472A (en) * | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| WO2009003998A2 (en) | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| CL2008001943A1 (es) * | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| CN101821240A (zh) | 2007-10-09 | 2010-09-01 | 默克专利有限公司 | 用作葡萄糖激酶激活剂的n-(吡唑-3-基)-苯甲酰胺衍生物 |
| KR20100134693A (ko) * | 2008-04-23 | 2010-12-23 | 교와 핫꼬 기린 가부시키가이샤 | 2-아미노퀴나졸린 유도체 |
| KR101269393B1 (ko) * | 2008-04-28 | 2013-05-29 | 아사히 가세이 파마 가부시키가이샤 | 페닐프로피온산 유도체 및 이의 용도 |
| ES2464461T3 (es) | 2008-09-22 | 2014-06-02 | Array Biopharma, Inc. | Compuestos de imidazo[1,2B]piridazina sustituidos como inhibidores de la TRK cinasa |
| AU2009300318A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| CN102292338B (zh) | 2008-12-08 | 2016-09-28 | 萌蒂制药国际有限公司 | 酪氨酸激酶蛋白受体拮抗剂 |
| EP2411007A4 (en) | 2009-03-27 | 2012-12-05 | Uab Research Foundation | MODULATION OF IRES-MEDIATED TRANSLATION |
| CN102906080A (zh) * | 2010-03-11 | 2013-01-30 | 百时美施贵宝公司 | 治疗丙型肝炎的化合物 |
| EP2558589A4 (en) * | 2010-04-15 | 2014-01-01 | Glaxosmithkline Llc | SIRTUIN ACTIVATORS AND ACTIVATION ASSAYS FOR THIS |
| SI2588475T1 (sl) | 2010-07-02 | 2015-12-31 | Gilead Sciences, Inc. | Kinazni inhibitorji za regulacijo apoptoznega signala |
| UA109150C2 (xx) | 2010-09-01 | 2015-07-27 | Аміди n-(тетразол-5-іл)- або n-(триазол-5-іл)арилкарбонової кислоти та їх застосування як гербіцидів | |
| US9079859B2 (en) | 2011-01-21 | 2015-07-14 | Auckland Uniservices Limited | Synthetic lethal targeting of glucose transport |
| EP2673270A1 (en) * | 2011-02-09 | 2013-12-18 | Syngenta Participations AG | Insecticidal compounds |
| AP2013007159A0 (en) * | 2011-04-05 | 2013-10-31 | Pfizer Ltd | Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of tropomyosin-related kinase |
| SG194902A1 (en) | 2011-05-13 | 2013-12-30 | Array Biopharma Inc | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
| LT2714668T (lt) | 2011-05-23 | 2017-04-10 | Merck Patent Gmbh | Tiazolo dariniai |
| KR20130077390A (ko) * | 2011-12-29 | 2013-07-09 | 제이더블유중외제약 주식회사 | 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체 |
| PT2900637T (pt) * | 2012-05-15 | 2017-11-15 | Novartis Ag | Derivados de amida de pirimidina, piridina e pirazina substituídos com tiazole ou imidazole e compostos relacionados como inibidores de abl1, abl2 e bcr-abl1 para tratamento do cancro, infecções virais específicas e disturbios do snc específicos |
| US9181261B2 (en) | 2012-05-22 | 2015-11-10 | Merck Sharp & Dohme Corp. | TrkA kinase inhibitors, compositions and methods thereof |
| WO2014003124A1 (ja) * | 2012-06-28 | 2014-01-03 | 富士フイルム株式会社 | 新規なアミド誘導体またはその塩 |
| EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| US10092537B2 (en) * | 2013-04-15 | 2018-10-09 | Renascience Co., Ltd. | Use for PAI-1 inhibitor |
-
2014
- 2014-03-26 WO PCT/CN2014/074145 patent/WO2015143654A1/en not_active Ceased
-
2015
- 2015-03-23 JP JP2016559249A patent/JP2017512794A/ja active Pending
- 2015-03-23 EP EP15769367.2A patent/EP3122346B1/en not_active Not-in-force
- 2015-03-23 CA CA2943858A patent/CA2943858A1/en not_active Abandoned
- 2015-03-23 AU AU2015236428A patent/AU2015236428B2/en not_active Ceased
- 2015-03-23 BR BR112016022069A patent/BR112016022069A2/pt not_active Application Discontinuation
- 2015-03-23 KR KR1020167029501A patent/KR20160128420A/ko not_active Withdrawn
- 2015-03-23 RU RU2016141646A patent/RU2672583C2/ru not_active IP Right Cessation
- 2015-03-23 WO PCT/US2015/021936 patent/WO2015148344A2/en not_active Ceased
- 2015-03-23 MX MX2016012480A patent/MX2016012480A/es unknown
- 2015-03-23 US US15/128,689 patent/US9815846B2/en active Active
- 2015-03-23 CN CN201580029747.2A patent/CN106794161A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512794A5 (enExample) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| JP5809267B2 (ja) | 血漿カリクレイン阻害剤としてのｎ−（（６−アミノ−ピリジン−３−イル）メチル）−ヘテロアリール−カルボキサミド類 | |
| US8314094B2 (en) | Benzoxazinone derivative | |
| JP2017508766A5 (enExample) | ||
| ES2708211T3 (es) | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas | |
| JP7517992B2 (ja) | 化合物及びその使用 | |
| KR102376354B1 (ko) | 6-(5-히드록시-1h-피라졸-1-일)니코틴아미드 유도체 및 ｐｈｄ의 저해제로서의 그의 용도 | |
| IL282840B1 (en) | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha | |
| US20080113967A1 (en) | Enzyme modulators and treatments | |
| JP2017512786A5 (enExample) | ||
| JP2017531679A (ja) | キナーゼ阻害剤として有用なインドールカルボキシアミド | |
| JP2016523911A5 (enExample) | ||
| MX2012008280A (es) | Compuestos y metodos. | |
| AU2020245349A1 (en) | Compounds and uses thereof | |
| JP2002528499A (ja) | Ｉｍｐｄｈ酵素のインヒビターであるアミノ核誘導化合物 | |
| CN103096718A (zh) | 可溶性鸟苷酸环化酶活化剂 | |
| KR20070007103A (ko) | 벤즈아미드 유도체 및 이의 글루코키나아제 활성화제로서의용도 | |
| AU2005267884A1 (en) | Potassium channel inhibitors | |
| CA2656715A1 (en) | Compounds and compositions as itpkb inhibitors | |
| RU2015111133A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2017523223A5 (enExample) | ||
| JP2014513122A5 (enExample) | ||
| AU2021322052A1 (en) | 2-(4-((5-(benzo[b]thiophen-3-yl)-1H-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (HDAC6) for use in treating e.g. peripheral neuropathy | |
| JP2019530708A5 (enExample) |